Global Xerostomia (Dry Mouth Disease) Therapeutics Market Overview (2022-2027)
• Historical Market Size (2021): US$ 683.45 Million
• Forecast CAGR (2022-2027): 3.75%
• Forecast Market Size (2027): US$ 862.79 Million
At 3.75% CAGR, Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size & Share to Surpass US$ 862.79 Million by 2027 | Industry Trends, Growth, Share, Opportunities, Statistics, Analysis & Forecast Report by IMARC Group.
What is a xerostomia (dry mouth disease) therapeutics market ?
Xerostomia, or dry mouth, represents symptoms or sensations of oral dryness that are generally caused, on account of a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, Alzheimer’s disorder, etc.
It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, mitigate bad breath and taste disorders, etc. As a result, xerostomia therapeutics are used across numerous hospitals and clinics to deal with decreased salivary gland function.
Request For Sample Report: https://www.imarcgroup.com/xerostomia-therapeutics-market/requestsample
Covid-19 Impact:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
What are the major market drivers in a xerostomia (dry mouth disease) therapeutics Market?
The growing incidences of dry mouth, especially among the geriatric population, owing to medicine side-effects of radiotherapy and chemotherapy and the inflating need for dry mouth relief products, are among the key factors stimulating the xerostomia (dry mouth disease) therapeutics market.
Moreover, the increasing utilization of several prescription-based toothpastes, vitamin gummies, medicines, etc., for treating Sjogren’s syndrome, Alzheimer’s diseases, human immunodeficiency virus (HIV), etc., that cause xerostomia is acting as another significant growth-inducing factor.
Besides this, the rising consumer awareness towards the early diagnosis of xerostomia, continuous enhancements in healthcare expenditures, and the development of diverse diagnostic technologies are positively influencing the global market. Furthermore, the easy availability of numerous therapeutic drugs and extensive investments in R&D activities are expected to fuel the xerostomia (dry mouth disease) therapeutics market over the forecasted period.
| Xerostomia (Dry Mouth Disease) Therapeutics Market Report Scope | |
| Report Coverage | Details |
| Market size value in 2021 | US$ 683.45 Million |
| Market forecast in 2027 | US$ 862.79 Million |
| Growth Rate | CAGR of 3.75% from 2022 to 2027 |
| Base year for estimation | 2021 |
| Historical data | 2016-2021 |
| Forecast period | 2022-2027 |
| Report coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, And Trends |
| Segments covered | Type, Drug Type And Distribution Channel |
| Regional scope | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Key companies profiled | 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc). |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Type:
- Artificial Saliva/Saliva Substitutes
- Salivary Stimulants
Breakup by Drug Type:
- OTC
- Prescription
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
List of Major Key Players:
The major players in the market are
3M Company
Biotene (GSK plc)
Parnell Pharmaceuticals Inc.
Quest Products LLC
Saliwell Ltd
Sun Pharmaceutical Industries Limited
and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800